Recro to Present at H.C. Wainwright Global Life Science Conference
March 02 2021 - 7:00AM
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development
and manufacturing organization (CDMO) dedicated to solving complex
formulation and manufacturing challenges for companies developing
oral solid dose drug products, today announced that its chief
executive officer, David Enloe, will deliver a corporate
presentation as part of the H.C. Wainwright Global Life Science
Conference. The conference, which will take place March 9-10, 2021,
is being conducted with a virtual format.
Details for the corporate presentation are as
follows:
- H.C. Wainwright Global Life
Science ConferenceDetails: Recro management will deliver a
corporate presentation and participate in 1-on-1 meetingsConference
dates: March 9-10, 2021Format: Virtual conference
About RecroRecro (NASD: REPH)
is a contract development and manufacturing organization (CDMO)
with capabilities from early feasibility to commercial
manufacturing. With an expertise in solving complex manufacturing
problems, Recro is a leading CDMO providing oral solid dosage form
development, end-to-end regulatory support, clinical and commercial
manufacturing, and packaging and logistics services to the global
pharmaceutical market.
In addition to our experience in handling DEA
controlled substances and developing and manufacturing modified
release oral solid dosage forms, Recro has the expertise to deliver
on our clients’ pharmaceutical development and manufacturing
projects, regardless of complexity level. We do all of this in our
best-in-class facilities, which total 120,000 square feet, in
Gainesville, Georgia.
For more information about Recro’s CDMO
solutions, visit recrocdmo.com.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Ryan D. Lake (CFO)
Recro
(484) 395-2436
ryan.lake@recroCDMO.com
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Apr 2023 to Apr 2024